Bicycle Therapeutics 株価情報 (NASDAQ: BCYC)

Bicycle Therapeutics (NASDAQ:BCYC) 株価情報

Bicycle Therapeutics

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics PLC

Most people assume that crypto's most popular financial instruments are tokens, but index funds are gaining significant traction. In traditional finance (TradFi), index-based funds have historically outperformed single-asset funds in terms of assets under management (AUM), providing investors with diversified exposure while mitigating risk.
While crypto ETFs, particularly <a href="https://www.sec.gov/newsroom/speeches-statements/gensler-statement-spot-bitcoin-011023">Bitcoin ETFs approved by the Securities and Exchange Commission (SEC) in January 2024</a>, have dominated recent market discussions, index funds offer a broader approach to digital asset investing. Instead of relying on the performance of a single asset, index funds track baskets of assets, creating the diversification that investors have long favored in traditional markets. 
In crypto, this approach holds similar potential. Instead of focusing on a single token like Bitcoin or Ethereum, index funds track multiple high-performing digital assets, offering exposure to the broader market while reducing concentration risk. The Bitwise 10 Crypto Index Fund was one of the first such crypto indexes, launched in 2017, and Fidelity and Bloomberg soon followed with its Bloomberg Galaxy Crypto Index in 2018.
As institutional adoption grows, multi-token index funds that take their unique approach to tracking, benchmarking, and reflecting the overall crypto sector could play a key role in bridging traditional investment strategies with the digital asset space.
<h2 class="wp-block-heading">Indexes spare the hassle &#8211; and risk &#8211; of investing in individual coins</h2>
The abundance of information about a coin &#8211; spread across white papers, discussion boards, social media platforms, and messaging apps &#8211; is difficult to keep up with for one coin, let alone the 1000s of digital assets at any given time. While ETFs save investors the inconvenience of buying, storing, and securing $BTC or other coins with forthcoming ETFs, investors must keep up with this real-time information firehose to manage their portfolios.
When there are many ETFs on the market, investors need to sift through piles of information before deciding which one to ultimately purchase. This is burdensome for most retail investors who simply want some exposure to crypto without getting into the technical details.&nbsp;
From this viewpoint, crypto indexes are a much better option: Investors can defer to the collective growth of a handful of top coins, eliminating the need to perform constant, extensive research on any one coin or ETF.
<h2 class="wp-block-heading">Indexes alleviate users from having to trade short-term </h2>
When investing stocks, short-term trading is often necessary. For instance, if you held shares of Nvidia ($NVDA), you might have felt compelled to buy or sell after the stock dropped following the Deepseek announcement.
In contrast, if you are an investor in the S&amp;P 500, which includes $NVDA, you would not need to respond to any market news. You could buy shares in the S&amp;P 500 and count on the overall growth of the market to withstand any changes to a single stock. Such investors can rest easy, knowing that their investment will always be bullish in the long-term (the S&amp;P boasts an average annual return of over <a href="https://www.investopedia.com/ask/answers/042415/what-average-annual-return-sp-500.asp">10% going back to 1957</a>).
Crypto indexes will be attractive in the same way. Instead of having to regularly take action on a specific token position, investors can simply buy shares in a crypto index and leave them untouched for the long-term. In the parlance of the crypto community, they can "hodl." Such investors can count on the continued growth of crypto to take their shares to new heights over time.
<h2 class="wp-block-heading">Indexes protect investors from the risks associated with FOMO </h2>
The fear of missing out (FOMO) is a real problem in crypto. When investors sit on the sidelines and see peers make money from different financial instruments, they may be prone to jump in and make ill-advised decisions.
FOMO is rampant now with meme coins, which Solana has made easier to launch than ever. A few cycles ago, there was also FOMO for non-fungible tokens and even play-and-earn tokens. All of these instruments are highly volatile. For example, the $SQUID token plummeted 99% in <a href="https://www.bbc.com/news/business-59129466">value in a matter of minutes</a>, while once popular NFT collections, <a href="https://www.theguardian.com/sport/2025/jan/14/almost-10000-images-of-tennis-balls-plunge-up-to-90-in-value-as-australian-open-appears-to-ditch-nfts?utm_source=chatgpt.com">such as those of tennis balls by the Australian Open</a>, were down by 90%.&nbsp;
Indexes can prevent investors from risky FOMO-based decision-making because they already have broad exposure. For example, they would not need to invest in meme coins because most popular indexes include Solana, the preferred blockchain for such assets. Similarly, they would not need to purchase any single NFTs because indexes always have Ethereum, the market leading blockchain for them.&nbsp;
Indexes will likewise give investors exposure to other major trends in the future, all without having to buy into individual assets that are highly risky on their own.
<h2 class="wp-block-heading">Indexing your Crypto Exposure&nbsp;</h2>
As crypto investment vehicles evolve, indexes represent the next logical step in providing retail investors with diversified, low-maintenance exposure to the market. While ETFs solve the challenge of buying and storing individual tokens, they still require investors to stay informed about specific assets. Indexes, on the other hand, simplify the investment process by spreading risk across multiple top-performing cryptocurrencies, much like how traditional stock indexes provide long-term stability.
By mitigating the risks of short-term trading and FOMO-driven decisions, indexes offer a more resilient approach to crypto investing. Whether the market shifts toward new trends or faces periods of volatility, indexes allow investors to participate in crypto's overall growth without the burden of constant research and rebalancing. Just as stock indexes have become a cornerstone of traditional investing, crypto indexes are poised to become a preferred vehicle for long-term, diversified exposure to the digital asset space.&nbsp;
Crypto, in short, operates like a book: The best guide is often the index.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

The Rise of Passive Investing: How Crypto is Evolving for Retail Investors

WIIM

Westlake shares are trading lower after the company reported worse-than-expected Q4 financial results.

Unity Software shares are trading lower. The company announced a $500 million convertible senior note offering.

A. Preview of timsTOF Ultra 2 system with novel Athena Ion Processor (AIP):
- Improves protein group identification in single-cell proteomics (SCP) by 15%-20%, and peptide identifications in SCP by 20%-25%
-Advances immunopeptidomics with 15%-20% more immunopeptide identifications
B. Launch of DeutEx&#x2122; software for hydrogen-deuterium exchange (HDX-MS) analysis
C. OmniScape&#x2122; 2025b: a breakthrough in top-down protein sequencing software
D. Advances in ProteoScape&#x2122; and Glycoproteomics software capabilities
E. Advances in TwinScape&#x2122; for cloud-based, AI-enabled proteomics quality monitoring

News

BRKR

Bruker Unveils 4D-Proteomics Breakthrough At US HUPO: Enhanced Single-Cell and Immunopeptidomics With timsTOF Ultra 2 And Athena Ion Processor

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $53 price target.

Price Target

Reiteration

Analyst Ratings

XENE

HC Wainwright & Co. Reiterates Buy on Xenon Pharmaceuticals, Maintains $53 Price Target

HC Wainwright &amp; Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Buy and maintains $74 price target.

SWTX

HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

MCHP

Microchip Technology Launched MPLAB XC Unified Compiler Licenses For Its MPLAB XC8, XC16, XC-DSC and XC32 C Compilers

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.laserphotonics.com%2F&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=Laser+Photonics+Corporation&amp;index=1&amp;md5=223dc3d3ec3a60d49aba12f490f75c5b">Laser Photonics Corporation</a> (LPC) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>), a leading global developer of industrial laser systems for cleaning and other material processing applications, in partnership with its sibling company Fonon Technologies, announced today the receipt of a second order for its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fonon.us%2Fproducts%2Fdefensetech-mrls-portable-finishing-laser-1020&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=DefenseTech+MRLS+Portable+Finishing+Laser&amp;index=3&amp;md5=223a07b9d89ac41eff38d88550ae268c">DefenseTech MRLS Portable Finishing Laser</a> (MF-1020) handheld cleaning system. This order was facilitated once again through their distribution partner, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fincrediblesupply.com%2F&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=Incredible+Supply+%26amp%3B+Logistics&amp;index=4&amp;md5=d2db227391448095ee4cf287ffd15f20">Incredible Supply &amp; Logistics</a> (ISL), an award-winning product distribution and third-party logistics (3PL) company.
The DTMF-1020 air-cooled handheld pulsed laser cleaning system, equipped with dual-axis technology, streamlines maintenance processes. This system will be utilized by the same Navy command in Virginia Beach that ordered the first unit.

Government

Regulations

LASE

Laser Photonics Secures Second Order for DefenseTech MRLS Laser Cleaning System

Earnings

ATCH

Reported Earlier, AtlasClear Holdings Q2 EPS $(1.11) Down From $2.22 YoY, Sales $2.75M

SOAR

Volato Announced Today That It Has Begun Bitcoin Mining Operations, Marking An Early But Significant Step In Its Broader Exploration Of Aviation-integrated Cryptocurrency Mining

Leerink Partners analyst Mike Kratky initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Outperform rating and announces Price Target of $28.

Initiation

BBNX

Leerink Partners Initiates Coverage On Beta Bionics with Outperform Rating, Announces Price Target of $28

<ul>
<li>SYMBRAVO demonstrated statistically significantly greater migraine treatment response compared to prior treatment with an oral CGRP inhibitor (p&lt;0.001, mTOQ-4 total score, primary endpoint)</li>
<li>2-hour pain freedom for most attacks reported at least half the time by 47.9% of patients after SYMBRAVO versus 1.0% after oral CGRPs (p&lt;0.001)</li>
<li>24-hour or greater sustained pain relief after a single dose reported by 47.9% of patients after SYMBRAVO versus 16.7% after oral CGRPs (p&lt;0.001)</li>
<li>Ability to quickly return to normal activities reported by 51.0% of patients after SYMBRAVO versus 11.5% after oral CGRPs (p&lt;0.001)</li>
<li>SYMBRAVO improved quality of life compared to after oral CGRPs (p&lt;0.001, MSQ)</li>
</ul>

AXSM

Axsome Therapeutics Unveils SYMBRAVO Success In EMERGE Phase 3 Trial, Paving The Way For Enhanced Migraine Treatment For CGRP Inhibitor Non-Responders

PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1).
"These results far exceeded our expectations for splicing correction following a single dose of PGN-EDODM1. Mis-splicing is the underlying cause of DM1 pathology, and we believe the mean splicing correction observed at 28 days following a single dose of PGN-EDODM1 at 10 mg/kg in the FREEDOM clinical trial surpasses those reported to date in multi-dose clinical trials of up to nine months in duration in patients with DM1. We believe this is a strong indicator of our EDO technology's potential to deliver therapeutic oligonucleotides to the nucleus and PGN-EDODM1's potential to address the underlying cause of disease," said James McArthur, PhD, President and CEO of PepGen. "We believe these results provide initial validation of PGN-EDODM1's ability to selectively bind the pathogenic CUG-repeat DMPK RNA and we look forward to evaluating PGN-EDODM1 with more doses over longer time periods in our FREEDOM2-DM1 multiple ascending dose study. Based on these initial results, we aim to build on the significant correction of mis-splicing observed in this single-dose study to potentially provide improved functional benefit for patients who currently have no available approved therapeutic options."

PEPG

PepGen Reports Early Data From FREEDOM-DM1 Trial for Myotonic Dystrophy

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and maintains $190 price target.

BCPC

HC Wainwright & Co. Reiterates Buy on Balchem, Maintains $190 Price Target

B of A Securities analyst Peter Henderson maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Buy and raises the price target from $149 to $175.

B of A Securities Maintains Buy on Live Nation Entertainment, Raises Price Target to $175

Mr. Doogue's ascension to CEO comes after 27 years of rising through the leadership ranks at Allegro, during which time he enabled many of Allegro's disruptive technologies, originally as an engineer and later as a business leader. Immediately prior to this promotion, Mr. Doogue served as Allegro's Executive Vice President and its first Chief Technology Officer (CTO), leading technology development and worldwide operations, which includes manufacturing, procurement, and quality. Mr. Doogue also previously served as the Company's Senior Vice President of Technology and Products, which included direct oversight of each of the Company's business units. As a testament to his roots as an engineer and technology innovator, Mr. Doogue personally holds 75 semiconductor-related U.S. patents.

ALGM

Allegro MicroSystems Names Mike Doogue As Chief Executive Officer

B of A Securities analyst John Murphy downgrades Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) from Neutral to Underperform and lowers the price target from $13 to $10.

Downgrades

RIVN

B of A Securities Downgrades Rivian Automotive to Underperform, Lowers Price Target to $10

IVVD

Invivyd Says FDA Declined Its Request To Expand Existing Emergency Use Authorization Of PEMGARDA To Include Treatment Of Mild-to-moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $185 price target.

NBIX

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D).
&nbsp;
Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways. Tregs are known to play a key role in the pathogenesis of T1D.1
Under the agreement, TrialNet will conduct the Phase 2 randomized, double-blind, placebo-controlled, clinical trial to investigate the safety and potential efficacy of rezpegaldesleukin in approximately 70 adults and children with new onset stage 3 T1D. Nektar will supply rezpegaldesleukin for the trial and will provide support for the study, including pharmacokinetic and other analyses. Nektar will retain all rights to the rezpegaldesleukin program under the collaboration.

Comments

Bicycle Therapeutics

ニュース

パートナーシップ

ベンジンガ・グローバル